Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;24(7):480-497.
doi: 10.1038/s41568-024-00699-2. Epub 2024 Jun 17.

Exploiting temporal aspects of cancer immunotherapy

Affiliations
Review

Exploiting temporal aspects of cancer immunotherapy

Rachael M Zemek et al. Nat Rev Cancer. 2024 Jul.

Abstract

Many mechanisms underlying an effective immunotherapy-induced antitumour response are transient and critically time dependent. This is equally true for several immunological events in the tumour microenvironment induced by other cancer treatments. Immune checkpoint therapy (ICT) has proven to be very effective in the treatment of some cancers, but unfortunately, with many cancer types, most patients do not experience a benefit. To improve outcomes, a multitude of clinical trials are testing combinations of ICT with various other treatment modalities. Ideally, those combination treatments should take time-dependent immunological events into account. Recent studies have started to map the dynamic cellular and molecular changes that occur during treatment with ICT, in the tumour and systemically. Here, we overlay the dynamic ICT response with the therapeutic response following surgery, radiotherapy, chemotherapy and targeted therapies. We propose that by combining treatments in a time-conscious manner, we may optimally exploit the interactions between the individual therapies.

PubMed Disclaimer

References

    1. Zemek, R. M. et al. Sensitizing the tumor microenvironment to immune checkpoint therapy. Front. Immunol. 11, 223 (2020). - PubMed - PMC - DOI
    1. Lesterhuis, W. J. et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat. Rev. Drug Discov. 16, 264–272 (2017). - PubMed - DOI
    1. Germain, R. N. The art of the probable: system control in the adaptive immune system. Science 293, 240–245 (2001). - PubMed - DOI
    1. Zemek, R. M. et al. Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nat. Protoc. 15, 1628–1648 (2020). - PubMed - DOI
    1. Combes, A. J., Samad, B. & Krummel, M. F. Defining and using immune archetypes to classify and treat cancer. Nat. Rev. Cancer 23, 491–505 (2023). - PubMed - DOI

Substances

LinkOut - more resources